CAI
Price
$24.49Alerts
Change
+$0.06 (+0.25%)
Updated
Nov 11 closing price
Capitalization
7.13B
Intraday BUY SELL Signals
RXRX
Price
$3.59Alerts
Change
+$0.04 (+1.13%)
Updated
Nov 11 closing price
Capitalization
1.89B
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CAI vs RXRX

CAI vs RXRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CAI vs. RXRX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAI is a Hold and RXRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CAI with price predictions
Nov 11, 2026

CAI's RSI Oscillator remains in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAI advanced for three days, in 46 of 67 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

CAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAI as a result. In 23 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for CAI turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 9 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

CAI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CAI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.049) is normal, around the industry mean (3.498). P/E Ratio (2.634) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.021) settles around the average of (130.981) among similar stocks. P/S Ratio (8.084) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for RXRX with price predictions
Nov 11, 2026

RXRX in +8.71% Uptrend, advancing for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RXRX advanced for three days, in 208 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXRX as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

RXRX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RXRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for RXRX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.063) is normal, around the industry mean (3.498). P/E Ratio (-3.520) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
CAI: Fundamental Ratings
CAI
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
46
PRICE GROWTH RATING
1..100
47
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
55

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CAIRXRX
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
69%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 9 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CAI: $24.49 vs. RXRX: $3.59)
Brand notoriety: CAI and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAI: 116% vs. RXRX: 71%
Market capitalization -- CAI: $7.13B vs. RXRX: $1.89B
CAI [@Biotechnology] is valued at $7.13B. RXRX’s [@Biotechnology] market capitalization is $1.89B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAI’s FA Score shows that 1 FA rating(s) are green while RXRX’s FA Score has 0 green FA rating(s).

  • CAI’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, CAI is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAI’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).

  • CAI’s TA Score: 4 bullish, 5 bearish.
  • RXRX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CAI is a better buy in the short-term than RXRX.

Price Growth

CAI (@Biotechnology) experienced а -26.28% price change this week, while RXRX (@Biotechnology) price change was -7.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

RXRX is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAI has been loosely correlated with TWST. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CAI jumps, then TWST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAI
1D Price
Change %
CAI100%
+0.25%
TWST - CAI
45%
Loosely correlated
-7.22%
RXRX - CAI
42%
Loosely correlated
+1.13%
BMEA - CAI
38%
Loosely correlated
+11.68%
ABCL - CAI
38%
Loosely correlated
-4.09%
ABSI - CAI
36%
Loosely correlated
+1.50%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+1.13%
CRSP - RXRX
66%
Loosely correlated
+1.33%
PRME - RXRX
62%
Loosely correlated
+10.26%
BEAM - RXRX
60%
Loosely correlated
+2.62%
ABSI - RXRX
60%
Loosely correlated
+1.50%
DNA - RXRX
57%
Loosely correlated
-14.65%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BMNU9.961.13
+12.80%
T-REX 2X Long BMNR Daily Target ETF (BMNU)
JQUA76.211.08
+1.44%
JPMorgan U.S. Quality Factor ETF (JQUA)
FIXP19.06-0.04
-0.22%
FolioBeyond Enhanced Fixed Inc Prm ETF
ETHD37.12-0.83
-2.19%
ProShares UltraShort Ether ETF (ETHD)
PSQ26.53-0.63
-2.32%
ProShares Short QQQ (PSQ)